2. Search Result
Search Result
Results for "

Camptothecin

" in MCE Product Catalog:

54

Inhibitors & Agonists

7

Natural
Products

2

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas
  • HY-16560
    Camptothecin
    Maximum Cited Publications
    33 Publications Verification

    Campathecin; (S)-(+)-Camptothecin; CPT

    		 Topoisomerase ADC Cytotoxin MicroRNA Influenza Virus Apoptosis Fungal Antibiotic Cancer Infection
    Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.
  • HY-114668
    Camptothecin-20(S)-O-propionate

    Camptothecin-20-O-propionate

    		 Topoisomerase Cancer
    Camptothecin-20(S)-O-propionate (CZ48), the C20-propionate ester of CPT, is a highly effective anticancer agent. Camptothecin-20(S)-O-propionate (CZ48) is a topoisomerase-Ι inhibitor.
  • HY-N8533
    Sodium Camptothecin

    		DNA/RNA Synthesis Cancer Infection
    Sodium Camptothecin is a plant alkaloid, with antitumor activity. Sodium Camptothecin is a reversible inhibitor of RNA synthesis. Sodium Camptothecin is an effective inhibitor of adenovirus replication. Sodium Camptothecin inhibits DNA synthesis and causes breaks in intracellular preformed viral DNA.
  • HY-156670
    Camptothecin analog-1

    		Others Others
    Camptothecin analog-1 (Comp 166) is a camptothecin analog.
  • HY-16560S
    Camptothecin-d5

    Campathecin-d5; (S)-(+)-Camptothecin-d5; CPT-d5

    		 Topoisomerase ADC Cytotoxin MicroRNA Influenza Virus Apoptosis Fungal Antibiotic Cancer Infection
    Camptothecin-d5 is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].
  • HY-12486
    FL118

    10,11-(Methylenedioxy)-20(S)-Camptothecin

    		 Survivin Apoptosis IAP Cancer
    FL118 (10,11-(Methylenedioxy)-20(S)-camptothecin), a Camptothecin (HY-16560) analogue, is a potent and orally active survivin inhibitor. FL118 binds to oncoprotein DDX5 (p68) to dephosphorylates and degrades DDX5. FL118 can be used for the research of cancer.
  • HY-156516
    10NH2-11F-Camptothecin

    		ADC Antibody Cancer
    10NH2-11F-Camptothecin is an antibody drug conjugates (ADC). 10NH2-11F-Camptothecin has anti-tumor activity. 10NH2-11F-Camptothecin can be used for cancer research.
  • HY-132160
    7-Aminomethyl-10-methyl-11-fluoro camptothecin

    		ADC Cytotoxin Cancer
    7-Aminomethyl-10-methyl-11-fluoro camptothecin is a cytotoxin of MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (HY-132158). 7-Aminomethyl-10-methyl-11-fluoro camptothecin can be used for the synthesis of camptothecin antibody-drug conjugate (ADC).
  • HY-153185
    Decyclohexanamine-Exatecan

    		Others Cancer
    Decyclohexanamine-Exatecan is a Camptothecin derivative, compound a, extracted from patent WO2020219287 A1.
  • HY-156517
    7Ethanol-10NH2-11F-Camptothecin

    		ADC Antibody Cancer
    7Ethanol-10NH2-11F-Camptothecin is an antibody drug conjugates (ADC). 7Ethanol-10NH2-11F-Camptothecin inhibits tumor growth. 7Ethanol-10NH2-11F-Camptothecin can be used for cancer research.
  • HY-156514
    MC-GGFG-AM-(10NH2-11F-Camptothecin)

    		ADC Antibody Cancer
    MC-GGFG-AM-(10NH2-11F-Camptothecin) is an antibody drug conjugates (ADC). MC-GGFG-AM-(10NH2-11F-Camptothecin) binds to the anti-TROp-2 antibody sacituzumab via a hydrolysable pH-sensitive linker and has anti-tumor activity. MC-GGFG-AM-(10NH2-11F-Camptothecin) can be used for cancer research.
  • HY-156515
    MC-GGFG-(7ethanol-10NH2-11F-Camptothecin)

    		Drug-Linker Conjugates for ADC Cancer
    MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) (compound 141) is a drug-linker conjugates for ADC. MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is a MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) with protease cleavable MC-GGFG linker.
  • HY-132158
    MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin

    		Drug-Linker Conjugates for ADC Cancer
    MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonal antibody (mAb) for the synthesis of camptothecin antibody-drug conjugate (ADC).
  • HY-107133
    Simmitecan hydrochloride

    		Topoisomerase Cytochrome P450 Cancer
    Simmitecan hydrochloride, a 9-substituted lipophilic Camptothecin (HY-16560) derivative, is a potent topoisomerase I inhibitor. Simmitecan hydrochloride is an anticancer agent.
  • HY-13670
    Lurtotecan

    GI147211; OSI-211

    		 Topoisomerase Cancer
    Lurtotecan (GI147211; OSI-211), a semisynthetic Camptothecin analog, is a topoisomerase I inhibitor. Lurtotecan has anticancer effects.
  • HY-B0063
    Gimatecan

    ST1481

    		 Topoisomerase Cancer
    Gimatecan (ST1481) is a potent topoisomerase I inhibitor. Gimatecan is an orally bioavailable camptothecin analogue with antitumor activity.
  • HY-15792
    (R)-FL118

    10,11-(Methylenedioxy)-20(R)-Camptothecin

    		 Others Cancer
    (R)-FL118 (10,11-(Methylenedioxy)-20(R)-camptothecin) is the R-enantiomer of FL118 (HY-12486). (R)-FL118 shows anticancer activity.
  • HY-148185
    T01-1

    		Others Cancer
    T01-1 is an anticancer agent (camptothecin derivative) with good anti-proliferative activity.
  • HY-153360
    MC-GGFG-AM-(10Me-11F-Camptothecin)

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells.
  • HY-139909
    CL2E-SN38

    		Drug-Linker Conjugates for ADC Cancer
    CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor.
  • HY-139909A
    CL2E-SN38 TFA

    		Drug-Linker Conjugates for ADC Cancer
    CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor.
  • HY-W177546
    CD00509

    		Phosphodiesterase (PDE) Cancer
    CD00509 is a Tdp1 inhibitor, with an IC50 value of 0.71 μM. CD00509 can sensitize breast cancer cells to Camptothecin (HY-16560). CD00509 has anti-tumor activity.
  • HY-148058
    Topoisomerase I inhibitor 8

    		Topoisomerase Cancer
    Topoisomerase I inhibitor 8 is a potent topoisomerase I inhibitor. Topoisomerase I inhibitor 8 is a hexacyclic analogue of camptothecin, and displays cytotoxic effect against tumor cells.
  • HY-132164
    Gly-7-MAD-MDCPT

    		Others Cancer
    Gly-7-MAD-MDCPT (compound 4b) is an anticancer agent. Gly-7-MAD-MDCPT is a Camptothecin (HY-16560) compound, it shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM.
  • HY-13622A
    Elomotecan

    BN 80927 free base

    		 Topoisomerase Cancer
    Elomotecan (BN 80927 free base) is a potent inhibitor of topoisomerases I and II. Elomotecan is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II.
  • HY-146025
    Antitumor agent-F10

    		Others Cancer
    Antitumor agent-F10 (Compound F10) is a camptothecin derivative. Antitumor agent-F10 is an orally–bioavailable and potent antitumor agent. Antitumor agent-F10 displays lower acute toxicity than SN-38 does and the solubility of F10 reached 9.86 μg/mL.
  • HY-13622
    Elomotecan hydrochloride

    BN 80927

    		 Topoisomerase Cancer
    Elomotecan hydrochloride (BN 80927) is a potent inhibitor of topoisomerases I and II. Elomotecan hydrochloride (BN 80927) is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan hydrochloride (BN 80927) reduces the proliferation of different tumor cells with higher potency than other anticancer agents of reference targeting topoisomerases I and II.
  • HY-14833
    Atiratecan

    TP300

    		 Topoisomerase Cancer
    Atiratecan (TP300) is a proagent of camptothecin analog CH0793076 (HY-107096). Atiratecan does not inhibit acetylcholinesterase (AChE) activities. Atiratecan shows antitumor activity against both breast cancer resistance protein (BCRP)-positive and -negative xenografts in mouse xenograft models.
  • HY-N2063
    12-Ethyl-9-hydroxycamptothecin

    		Topoisomerase Others
    12-Ethyl-9-hydroxycamptothecin is a derivative of Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM.
  • HY-N2108
    7-Ethylcamptothecin

    		Others Cancer
    7-Ethylcamptothecin is one of camptothecin analogues. camptothecin (CPT), a cytotoxic alkaloid isolated from Camptotheca acuminata, is shown to have strong antitumor activity against L1210 leukemia and Walker 256 carcinosarcoma models.
  • HY-13566A
    Belotecan hydrochloride
    1 Publications Verification

    CKD-602

    		 Topoisomerase Cancer
    Belotecan hydrochloride (CKD-602 hydrochloride), a Topoisomerase I inhibitor, is a synthetic camptothecin derivative.
  • HY-16228
    Genz-644282
    2 Publications Verification

    		 Topoisomerase Cancer
    Genz-644282 is a non-camptothecin topoisomerase I inhibitor, used for cancer research.
  • HY-128979
    Deruxtecan analog 2

    		Drug-Linker Conjugates for ADC Cancer
    Deruxtecan analog 2 (example 9 P3) is a Deruxtecan (HY-13631E) analog. Deruxtecan analog 2 is a agent-linker conjugate composed of Camptothecin (HY-16560) and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC.
  • HY-13566AS
    Belotecan-d7 hydrochloride

    		Topoisomerase Cancer
    Belotecan-d7 (hydrochloride) is the deuterium labeled Belotecan hydrochloride. Belotecan hydrochloride (CKD-602 hydrochloride), a Topoisomerase I inhibitor, is a synthetic camptothecin derivative[1][2].
  • HY-100309
    9-Aminocamptothecin

    9-Amino-20(S)-Camptothecin; 9-Amino-CPT

    		 Topoisomerase Cancer
    9-Aminocamptothecin (9-Amino-CPT) is a topoisomerase I inhibitor with potent anticancer activity.
  • HY-13566
    Belotecan

    CKD-602 free base

    		 Topoisomerase Apoptosis Cancer
    Belotecan (CKD-602 free base) is a DNA topoisomerase I inhibitor. Belotecan induces cell apoptosis and cell-cycle arrest. Belotecan is a camptothecin analogue with anti-tumor effects, it can be used for the research of cancer.
  • HY-13744
    Rubitecan

    RFS 2000; 9-NitroCamptothecin

    		 Topoisomerase Cancer
    Rubitecan (RFS 2000), a Camptothecin derivative, is an orally active topoisomerase I inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells.
  • HY-125331
    DRF-1042

    		Topoisomerase ADC Cytotoxin Cancer
    DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype.
  • HY-146094
    Antitumor agent-63

    		Topoisomerase Cancer
    Antitumor agent-63 (Compound 40), a 20 (S)-O-linked camptothecin (CPT) glycoconjugate, is an antitumor agent without toxicity towards normal cells. Antitumor agent-63 shows high stability and very weak direct topoisomerase I (Topo I) inhibition.
  • HY-107096
    CH-0793076

    TP3076

    		 Topoisomerase Cancer
    CH-0793076 (TP3076), a hexacyclic camptothecin analog, is active drug and major metabolite of TP300. CH-0793076 inhibits DNA topoisomerase I with an IC50 of 2.3 μM. CH-0793076 is efficacious against cells expressing BCRP (breast cancer resistance protein).
  • HY-N0446
    10-Methoxycamptothecin

    		ADC Cytotoxin Cancer
    10-Methoxycamptothecin is a natural bioactive derivative of camptothecin (CPT) isolated from Camptotheca acuminata, and has been confirmed to possess high anti-cancer properties. 10-Methoxycamptothecin has higher cytotoxicity than 10-hydroxycamptothecin by testing antitumor activity against 2774 cell lines.
  • HY-130572
    Azido-PEG5-acid

    		PROTAC Linkers ADC Linker Cancer Inflammation/Immunology
    Azido-PEG5-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs, such as the conjugate CPT-APO (CPT: Camptothecin (HY-16560)). Azido-PEG5-acid is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-120574
    TH1338

    		Others Cancer
    TH1338 (compound 3b), an orally active camptothecin derivative and a potent chemotherapeutic agent for cancer, demonstrates excellent cytotoxic potency against human tumor cell lines in vitro. TH1338 (compound 3b) possesses significant brain penetration, favorable efflux pump properties, and hematological toxicity profile.
  • HY-107096B
    CH-0793076 TFA

    TP3076 TFA

    		 Topoisomerase Cancer
    CH-0793076 (TP3076) TFA, a hexacyclic camptothecin analog, is active drug and major metabolite of TP300. CH-0793076 TFA inhibits DNA topoisomerase I with an IC50 of 2.3 μM. CH-0793076 TFA is efficacious against cells expressing BCRP (breast cancer resistance protein).
  • HY-W021377C
    Exatecan Intermediate 4 dihydrochloride

    		Cancer
    Exatecan Intermediate 4 dihydrochloride is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers.
  • HY-132161
    MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT

    		Drug-Linker Conjugates for ADC Cancer
    MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a Camptothecin-linker compound extracted from patent WO2019195665A1, example 4-1. MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a agent-linker conjugate for antibody-drug conjugate (ADC).
  • HY-W021377
    Exatecan Intermediate 2

    		ADC Cytotoxin Cancer
    Exatecan Intermediate 2 (compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers.
  • HY-W021377A
    Exatecan Intermediate 2 hydrochloride

    		ADC Cytotoxin Cancer
    Exatecan Intermediate 2 hydrochloride (compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers.
  • HY-42487
    Exatecan Intermediate 1

    		ADC Cytotoxin Cancer
    Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers.
  • HY-W021377B
    Exatecan Intermediate 4

    		Cancer
    Exatecan Intermediate 4 (compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers.
  • HY-42487B
    (R)-Exatecan Intermediate 1

    		Cancer
    (R)-Exatecan Intermediate 1 is an isomer of Exatecan Intermediate 1 (HY-42487). Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631), a camptothecin-based anticancer agent. Exatecan inhibits tumor growth by interfering with the proliferation and division of tumor cells by interacting with DNA. Exatecan is primarily used in research into a variety of cancers including ovarian, lung and breast cancer.
  • HY-42487A
    (rac)-Exatecan Intermediate 1

    		ADC Cytotoxin Cancer
    (rac)-Exatecan Intermediate 1 is an isomer of Exatecan Intermediate 1 (HY-42487). Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631), a camptothecin-based anticancer agent. Exatecan inhibits tumor growth by interfering with the proliferation and division of tumor cells by interacting with DNA. Exatecan is primarily used in research into a variety of cancers including ovarian, lung and breast cancer.
  • HY-145291
    CPT-Se4

    		Topoisomerase Apoptosis Cancer
    CPT-Se4, a selenoproagent of Camptothecin (CPT), shows improved potency in killing cancer cells and inhibiting tumor growth. CPT-Se4 decreases the GSH/GSSG ratio and total thiols, elevates the ROS level in Hep G2 cells, and eventually induces apoptosis of cancer cells. CPT-Se4 shows cytotoxicity against HeLa, Hep G2, A549, and SMMC-7721 cells (IC50= 2.54-6.4 μM).
  • HY-145290
    CPT-Se3

    		Topoisomerase Apoptosis Cancer
    CPT-Se3, a selenoproagent of Camptothecin (CPT), shows improved potency in killing cancer cells and inhibiting tumor growth. CPT–Se3 decreases the GSH/GSSG ratio and total thiols, elevates the ROS level in Hep G2 cells, and eventually induces apoptosis of cancer cells. CPT-Se3 shows cytotoxicity against HeLa, Hep G2, A549, and SMMC-7721 cells (IC50= 2.19-4.7 μM).